INO
Inovio Pharmaceuticals·NASDAQ
--
--(--)
--
--(--)
3.86 / 10
Netural
Fund flow data show a good score of 7.72/10, with positive block, large, and extra-large inflows, although overall trend is negative. This suggests institutional accumulation despite short-term pullbacks. Analyst coverage is limited to one institution (Piper Sandler) with a 100% Buy rating over the last 20 days, but historical win rate is 0.0%, indicating limited reliability. Sentiment is neutral, and the stock's price rise of 9.93% does not align with the weighted analyst expectations, highlighting a mismatch.
Fund Flow Rating
Analyst RatingBuy
Wall Street Opinions
Buy
Strong Buy
0%
Buy
100%
Hold
0%
Sell
0%
Strong Sell
0%
Date2025-11-14
InstitutionPiper Sandler
Times predicted2
Historical Win Rate0.0%
Is money flowing into or out of INO?
- INO holds a Bearish analyst rating, with 100% of experts assigning a Buy grade. Factoring in net Outflows from order flow data, the comprehensive Sentiment Score stands at 3.86/10 (Netural).
